Equities research analysts at Sanford C. Bernstein began coverage on shares of FRESENIUS SE &/S (OTCMKTS:FSNUY) in a report released on Tuesday, The Fly reports. The firm set a “market perform” rating on the stock.
Separately, ValuEngine upgraded FRESENIUS SE &/S from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the company. FRESENIUS SE &/S presently has an average rating of “Hold” and an average target price of $15.00.
FSNUY traded up $0.02 during midday trading on Tuesday, hitting $13.31. The company’s stock had a trading volume of 9,100 shares, compared to its average volume of 22,845. The company has a current ratio of 1.09, a quick ratio of 0.84 and a debt-to-equity ratio of 0.81. FRESENIUS SE &/S has a 52-week low of $11.00 and a 52-week high of $15.26. The firm has a 50-day moving average price of $12.14 and a two-hundred day moving average price of $12.75. The firm has a market cap of $29.58 billion, a P/E ratio of 16.85, a PEG ratio of 2.01 and a beta of 1.25.
Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
See Also: What are gap-down stocks?
Receive News & Ratings for FRESENIUS SE &/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FRESENIUS SE &/S and related companies with MarketBeat.com's FREE daily email newsletter.